Myeloma Drug Candidate Gets Breakthrough Status
Myeloma Drug Candidate Gets Breakthrough Status image
Myeloma Drug Candidate Gets Breakthrough Status
Posted Nov 03, 2017

By: Greg Brozeit GlaxoSmithKline (GSK) announced that an antibody being developed to target BCMA in myeloma received the Food & Drug Administration’s (FDA) “Breakthrough Therapy Designation” on November 2, 2017. The new agent, GSK2857916, was granted similar status by the European Medicines Agency (EMA), the European Union’s counterpart to FDA, in October.  Both designations are based on phase 1 clinical trial data that will be presented on December 11 at the annual American Society of Hematology (ASH) meeting in Atlanta. The GSK therapy is currently being tested as a single agent in “treatment of relapsed and refractory multiple myeloma patients whose prior therapy included a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody.” A GSK spokesman announced that in addition being used as a single agent, the longer-term goal is to develop clinical trials “in combination with other approved therapies.” According to a law passed in 2012, the FDA may grant breakthrough status to any drug “intended…to treat a serious or life threatening disease” which “may demonstrate substantial improvement over existing therapies.” The Myeloma Crowd and SparkCures will publicize more information about the GSK drug candidate once the information when clinical trials are opened. BCMA is also one of the targets of CAR T cell research being funded by the Myeloma Crowd Research Initiative.

The author Greg Brozeit

about the author
Greg Brozeit

Greg Brozeit has been engaged in myeloma patient advocacy since 1998. He began working with the Myeloma Crowd in 2015. Prior to that, he consulted with Dr. Bart Barlogie at the University of Arkansas after working with the International Myeloma Foundation for 15 years, where he inaugurated the public policy advocacy program, patient support group outreach and IMF Europe, organizing more than 100 physician and patient education programs. He earned his BA in political science from Loyola University in New Orleans and lives in northeast Ohio.

More Myeloma News Articles

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Bristol Myers Squibb
Janssen Oncology

Follow Us

facebook instagram twitter youtube

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation / Myeloma Crowd is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811